In Vivo Model Development for Phenylketonuria

Ace Therapeutics offers a comprehensive in vivo animal model development service tailored for Phenylketonuria (PKU) research and therapeutic evaluation. Leveraging advanced genetic, dietary, and chemically-induced murine models, we enable our clients to accelerate the discovery and preclinical assessment of novel PKU treatments with scientifically validated, translationally relevant platforms.

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to the accumulation of phenylalanine and resulting in severe neurological impairment if untreated. Accurate animal models are essential for understanding PKU pathophysiology, evaluating therapeutic efficacy, and translating findings to human patients. Ace Therapeutics utilizes various strains of Mus musculus, including BTBR(ENU2), BTBR-Pahenu2/J, C57BL/6, ENU2, FRG, and NOD, each selected for their genetic compatibility, metabolic characteristics, and ability to recapitulate the clinical manifestations of PKU. These models provide robust platforms for drug screening, gene therapy, dietary intervention, and cell-based therapeutic studies, ensuring that preclinical findings hold strong translational relevance.

Genetic Models

Genetic models of PKU at Ace Therapeutics are established through targeted mutations or knockouts of the Pah gene in mouse strains such as BTBR(ENU2), BTBR-Pahenu2/J, C57BL/6, and ENU2. Some models also involve knockdown or knockout of related transporters (e.g., Slc6a19) or conditional transgenic PAH expression. The methodology includes CRISPR/Cas9-mediated gene editing, ENU mutagenesis, and transgenic techniques to mimic the human PKU genotype and phenotype. Key advantages include high construct validity, stable inheritance of the disease phenotype, and suitability for long-term studies. These models are primarily used for evaluating gene therapies, enzyme replacement, small molecule drugs, and understanding PKU pathogenesis.

Chemically-Induced Models

Chemically-induced PKU models are generated by administering (S)-phenylalanine or other phenylalanine analogs to wild-type or genetically predisposed mice. This approach rapidly elevates systemic phenylalanine levels, transiently mimicking the biochemical and neurological features of PKU. The major advantage is the ability to induce PKU-like states in a controlled, reversible manner, facilitating acute pharmacodynamic and pharmacokinetic studies. These models are ideal for early-stage efficacy screening, toxicology, and metabolic pathway investigations.

Dietary Models

Dietary models involve placing genetically modified or wild-type mice on phenylalanine-deficient or controlled diets to modulate disease severity and study therapeutic interventions under dietary management conditions. This methodology is particularly relevant for assessing the impact of dietary therapies and adjunct treatments in the context of standard-of-care PKU management. Advantages include the ability to model real-world patient scenarios, evaluate dietary compliance, and study gene-diet interactions. Dietary models support research into nutritional therapies, adjunct pharmacological agents, and metabolic outcomes.

Xenograft and Immunodeficient Models

Ace Therapeutics also offers advanced xenograft models, such as the FRG mouse engrafted with human hepatocytes, and immunodeficient strains like NOD-SCID. These models enable the evaluation of cell-based therapies, human-specific gene editing, and long-term engraftment studies. The primary advantage is the ability to assess human cell or gene therapy efficacy and safety in an in vivo environment. Applications include humanized therapy development, immune response characterization, and translational bridging studies.

Ace Therapeutics provides a complete PKU animal model solution, from model selection and custom generation to in vivo efficacy testing and comprehensive data analysis. Our service encompasses: (1) consultation for optimal model and strain selection based on research objectives; (2) generation and validation of genetic, dietary, and chemically-induced PKU models; (3) execution of therapeutic studies, including drug, gene, enzyme, dietary, and cell-based interventions; (4) detailed phenotypic and biochemical assessments, including plasma and brain phenylalanine levels, neurobehavioral testing, enzyme activity assays, and histopathological analysis; (5) advanced analytical capabilities such as LC-MS/MS, ELISA, immunohistochemistry, and next-generation sequencing; and (6) rigorous quality control measures, including genotyping, phenotype validation, and standardized operating procedures to ensure reproducibility and data integrity.

Partnering with Ace Therapeutics ensures access to a scientifically robust, end-to-end in vivo PKU model development and testing platform. Our expertise, state-of-the-art facilities, and commitment to quality empower clients to advance their PKU research with confidence, accelerating translational breakthroughs and therapeutic innovation. Contact us today to discuss your project needs and discover how our tailored animal model solutions can drive your PKU research forward.